LLC Has $934000 Stake in Teva Pharmaceutical Industries Limited (TEVA)

Xavier Trudeau
Août 13, 2017

Teacher Retirement System of Texas lowered its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 12.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. Teva Pharmaceutical Industries Limited accounts for 1.9% of Van Strum & Towne Inc.'s holdings, making the stock its 24th largest position. HL Financial Services LLC's holdings in Teva Pharmaceutical Industries Limited were worth $706,000 at the end of the most recent quarter.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Greylin Investment Mangement Inc. raised its stake in shares of Teva Pharmaceutical Industries Limited by 36.9% in the second quarter. Agf Investments Inc. owns 1,884,366 shares valued at $62,623,000. Salem Investment Counselors Inc. raised its stake in Teva Pharmaceutical Industries Limited by 0.4% in the first quarter. Schroder Investment Management Group augmented its ownership by buying 542,737 shares an increase of 13.8% in the quarter. FCA Corp TX purchased a new position in shares of Teva Pharmaceutical Industries Limited during the second quarter worth approximately $266,000. Cribstone Capital Management LLC now owns 3,141 shares of the company's stock worth $101,000 after buying an additional 100 shares in the last quarter. Heritage Investors Management Corp boosted its stake in shares of Teva Pharmaceutical Industries Limited by 17.5% in the first quarter. Bank Hapoalim BM now owns 11,673 shares of the company's stock worth $375,000 after buying an additional 980 shares in the last quarter. Finally, Sterling Investment Advisors Ltd. raised its stake in Teva Pharmaceutical Industries Limited by 2.6% in the first quarter.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) traded up 0.64% during mid-day trading on Wednesday, hitting $17.30. The firm has a 50-day moving average price of $29.64 and a 200-day moving average price of $31.56. Teva Pharmaceutical Industries Limited has a one year low of $16.81 and a one year high of $55.39. The company's market capitalization is $17.58 billion.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its quarterly earnings results on Thursday, August 3rd.

In the last earnings report the EPS was $0.08 and is expected to be $4.39 for the current year with 1,016,000,000 shares now outstanding. Company's sales went up 12.9% compared with the same period in the prior year. on consensus, Financial experts predict that Teva Pharmaceutical Industries to post $4.32 earnings per share for the financial year. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The company's revenue for the quarter was up 12.9% on a year-over-year basis. Teva Pharmaceutical Industries Limited's revenue was up 12.9% compared to the same quarter a year ago.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 14th. Investors of record on Tuesday, August 29th will be paid a dividend of $0.085 per share. The dividend yield will be $6.04. The ex-dividend date will be Thursday the 1st of June 2017. Teva Pharmaceutical Industries Limited's dividend payout ratio (DPR) is now -18.95%.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of U.S. and global copyright and trademark legislation. The legal version of this piece of content can be accessed at https://sportsperspectives.com/2017/08/12/teacher-retirement-system-of-texas-sells-135859-shares-of-teva-pharmaceutical-industries-limited-teva.html.

Several analysts recently weighed in on the company. Vetr upgraded shares of Teva Pharmaceutical Industries Limited from a "hold" rating to a "buy" rating and set a $34.17 target price on the stock in a research report on Monday, July 24th.

04/24/2017 - Teva Pharmaceutical Industries Limited had its "buy" rating reiterated by analysts at Citigroup. On average, analysts forecast that Teva Pharmaceutical Industries Limited will post $4.32 earnings per share for the current year. Finally, Credit Suisse Group reaffirmed an "outperform" rating and issued a $39.00 price objective on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday. Also, there are 0 buy, 0 sell and 2 strong sell ratings, collectively assigning a 2.96 average brokerage recommendation. Zacks Investment Research upgraded shares of Teva Pharmaceutical Industries Limited from a "sell" rating to a "hold" rating in a research report on Monday, July 17th. The company has a consensus rating of Hold and a consensus target price of $37.69. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The corporation operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

D'autres rapports CampDesrEcrues

Discuter de cet article

SUIVRE NOTRE JOURNAL